News stories about Agios Pharmaceuticals (NASDAQ:AGIO) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 43.4801407630134 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at 71.225 on Wednesday. Agios Pharmaceuticals has a 12-month low of $39.24 and a 12-month high of $71.95. The firm has a 50-day moving average price of $64.81 and a 200 day moving average price of $56.40. The stock’s market cap is $3.45 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The firm had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. During the same period in the previous year, the company earned ($1.47) earnings per share. The business’s revenue for the quarter was up 62.1% on a year-over-year basis. Equities research analysts predict that Agios Pharmaceuticals will post ($7.08) EPS for the current fiscal year.
A number of analysts recently commented on the company. SunTrust Banks, Inc. reiterated a “buy” rating and set a $80.00 price objective (up previously from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Janney Montgomery Scott reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, August 1st. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $50.00 to $80.00 in a research report on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $75.20.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/11/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-agios-pharmaceuticals-agio-share-price.html.
In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 3,500 shares of the company’s stock in a transaction dated Wednesday, July 19th. The stock was sold at an average price of $56.14, for a total value of $196,490.00. Following the transaction, the director now directly owns 86,697 shares of the company’s stock, valued at approximately $4,867,169.58. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO David P. Schenkein sold 27,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $59.95, for a total value of $1,618,650.00. Following the completion of the transaction, the chief executive officer now directly owns 3,000 shares in the company, valued at $179,850. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 228,408 shares of company stock worth $14,976,478. Insiders own 10.55% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.